Literature DB >> 15184530

Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales.

Fiona W Scott1, Tyrone L Pitt1.   

Abstract

Most past studies of cross-infection with Pseudomonas aeruginosa among cystic fibrosis (CF) patients in the UK suggest that it is a rare occurrence. However, two recent reports of highly transmissible strains in patients in regional centres in England (Liverpool and Manchester) have raised questions as to the extent of the problem and prompted a nationwide survey to establish the distribution of P. aeruginosa strain genotypes among these patients. Isolates of P. aeruginosa were requested from over 120 hospitals in England and Wales and a sample size of approximately 20% of the CF patient population in each centre was recommended. In total, 1225 isolates were received from 31 centres (range 1 to 330). Single patient isolates were typed by SpeI macrorestriction and PFGE. A panel of strains of the common genotypes including representatives of reported transmissible strains was assembled and further characterized by fluorescent amplified fragment length polymorphism (FAFLP) genotyping. At least 72% of all patients harboured strains with unique genotypes. Small clusters of related strains were evident in some centres, presumably indicating limited transmission of local strains. The most prevalent strain was indistinguishable from that previously described as the 'Liverpool' genotype, and accounted for approximately 11% of patient isolates from 15 centres in England and Wales. The second most common genotype (termed Midlands 1) was recovered from 86 patients in nine centres and the third genotype, which matched closely the PFGE profile of Clone C, a genotype originally described in Germany, was found in eight centres and was isolated from 15 patients. A fourth genotype, identical to the published Manchester strain, was found in three centres. FAFLP analysis revealed some microheterogeneity among strains of the Liverpool genotype but all isolates of this genotype were positive by PCR for a strain-specific marker. These data suggest that cross-infection with P. aeruginosa has occurred both within and widely between CF centres in England and Wales. The two most common genotypes accounted for more than one-fifth of patients' isolates examined and transmissible genotypes were found in all but three centres studied. These results emphasize the need for continued surveillance of P. aeruginosa genotypes in CF patients to provide informed infection control policy in treatment centres.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184530     DOI: 10.1099/jmm.0.45620-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  56 in total

1.  Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Authors:  Joanne L Fothergill; Eilidh Mowat; Martin J Walshaw; Martin J Ledson; Chloe E James; Craig Winstanley
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

2.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Developing an international Pseudomonas aeruginosa reference panel.

Authors:  Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley
Journal:  Microbiologyopen       Date:  2013-11-11       Impact factor: 3.139

5.  Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa.

Authors:  A Deplano; O Denis; L Poirel; D Hocquet; C Nonhoff; B Byl; P Nordmann; J L Vincent; M J Struelens
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

6.  Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  V Waters; J E A Zlosnik; Y C W Yau; D P Speert; S D Aaron; D S Guttman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-29       Impact factor: 3.267

7.  A diagnostic PCR assay for the detection of an Australian epidemic strain of Pseudomonas aeruginosa.

Authors:  Heidi L Williams; Lynne Turnbull; Susan J Thomas; Anna Murphy; Tim Stinear; David S Armstrong; Cynthia B Whitchurch
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-07-16       Impact factor: 3.944

8.  Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model.

Authors:  Akinobu Kamei; Andrew Y Koh; Mihaela Gadjeva; Gregory P Priebe; Stephen Lory; Gerald B Pier
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

9.  Pseudomonas aeruginosa population structure revisited.

Authors:  Jean-Paul Pirnay; Florence Bilocq; Bruno Pot; Pierre Cornelis; Martin Zizi; Johan Van Eldere; Pieter Deschaght; Mario Vaneechoutte; Serge Jennes; Tyrone Pitt; Daniel De Vos
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

10.  Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis.

Authors:  C E Wainwright; M W France; P O'Rourke; S Anuj; T J Kidd; M D Nissen; T P Sloots; C Coulter; Z Ristovski; M Hargreaves; B R Rose; C Harbour; S C Bell; K P Fennelly
Journal:  Thorax       Date:  2009-07-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.